A Phase 3b, Multi-Center, Randomized-withdrawal, Placebo-Controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45-120mg/day, Split-dose) in Subjects with Chronic Kidney Disease Stage 4 due to Autosomal Dominant Polycystic Kidney Disease.
New clues to non-alcoholic fatty liver disease (NAFLD), which
affects nearly all obese adults and a rising percentage of obese
children, have been reported in a paper by senior author Susan
S. Baker MD, PhD.
Anne B. Curtis, MD, SUNY Distinguished Professor and Charles and
Mary Bauer Professor and chair of the Department of Medicine, is a
member of the committee that has issued a new practice guideline
for treating sudden cardiac death (SCD).